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Abstract Treatment of neonatal rat islets of Langerhans with
combined cytokines (interleukin-1L 10310 M, tumour necrosis
factor-K 10310 M, interferon-Q 5 U/ml) led to extensive cell
death, which was potentiated by Fas activation with the anti-Fas
cytolytic antibody JO2. Pre-treatment with insulin (25 ng/ml) or
insulin-like growth factor-1 (1038 M) gave only partial
protection against cell killing, but prevented the Fas-mediated
component. In the absence of cytokine treatment, Fas-mediated
killing was not observed.
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1. Introduction
Cytokines inhibit insulin secretion in rat islets largely
through the formation of nitric oxide via inducible nitric oxide
synthase [1]. Cytokines, including interleukin-1L (IL-1L), are
also able to induce cell death (necrotic and apoptotic), in rat
[2] and human pancreatic islets [3,4] and insulin containing
cell lines [2,5]. We have previously shown that insulin-like
growth factor-1 (IGF-1) protects rat islets from cytokine-
mediated apoptosis, partly through decreasing nitric oxide
synthase (NOS) expression [6]. It has recently been reported
that IGF-2 protects rat islets from cytotoxic and apoptotic
e¡ects of cytokines [7]. Insulin administered in vivo protects
non-obese diabetic (NOD) mice from insulitis and diabetes [8]
and may protect islets from cytokine inhibition or cell death
but in vitro protective e¡ects have not previously been dem-
onstrated.
There is evidence that the selective destruction of human [9]
and NOD mouse [10] pancreatic L-cells may be the result of
apoptosis, although this is not seen in all cases (V. Hadjivas-
siliou and I. Green, submitted for publication). One of the
mediators of apoptosis believed to be involved in L-cell apop-
tosis is Fas (Apo-1, CD95), a 45 kDa transmembrane cell
surface receptor protein and a member of the tumour necrosis
factor (TNF) receptor family [11]. The interaction of a func-
tional Fas receptor with its ligand, FasL, or with an agonistic
antibody results in apoptosis ([12] and see review [13]). There
is growing evidence of a role for Fas-mediated apoptosis in
the destruction of L-cells seen in the development of insulin-
dependent diabetes [14]. Fas expression can be induced on
pancreatic L-cells in human [9] and mouse islets of Langer-
hans [11,15] through priming with the cytokine, IL-1L, but it
has not previously been reported on rat L-cells.
The aims of this study were (1) to determine whether
growth factors (IGF-1, insulin) would protect neonatal rat
islets from apoptosis induced by the combined cytokines IL-
1L, TNFK and interferon-Q (IFN-Q), (2) to see if combined
cytokine treatment induces Fas expression on rat islets and
(3) to determine if growth factor protection against cytokine-
induced apoptosis occurs via interference with the Fas-medi-
ated apoptotic pathway.
2. Materials and methods
Reagents were obtained from the following sources: tissue culture
RPMI 1640 and foetal calf serum from Gibco BRL (Paisley, UK);
anti-Fas antibody, JO2 (PharMingen, San Diego, CA, USA). The
cytokines used were human recombinant IL-1L (a gift from Glaxo
Wellcome, Stevenage, UK), human recombinant TNF-K and IGF-1
(gifts from the National Institute for Biological Standards and Con-
trol, Potters Bar, UK) and rat recombinant IFN-Q (Genzyme, West
Malling, Kent, UK).
2.1. Islet isolation and culture
Islets of Langerhans were isolated under aseptic conditions from
collagenase-digested pancreata of 7^12 day old Sprague-Dawley rats
or Lewis rats [16]. Batches of 150^500 islets were cultured in RPMI
1640 medium containing 5.5 mM glucose, penicillin (50 U/ml), strep-
tomycin (50 Wg/ml) and 5% foetal calf serum for 2 days prior to
growth factor pre-treatment and cytokine treatment.
2.2. Treatment of islets with growth factors and cytokines
Groups of up to 300 islets were treated in complete RPMI culture
medium in 60 mm Petri dishes and cultured for 48 h at 37‡C in an
atmosphere of 5% CO2 :95% air before analysis. Growth factors used
were IGF-1 (1038 M) and insulin (25 ng/ml). Islets were treated with
growth factors for 24 h. Where growth factor pre-treatment occurred,
prior to cytokine treatment, the same dish was used and cytokines
were added in fresh medium to the islets for a further 48 h unless
otherwise stated.
Isolated islets were incubated at 37‡C with the human recombinant
cytokines IL-1L (10310 M) and TNF-K (10310 M) and rat recombi-
nant IFN-Q (5 U/ml), except in Fig. 1 where concentrations were IL-
1L and TNF-K (5U10311 M), IFN-Q (2 U/ml).
2.3. Fas activation
Pancreatic islets, 200 from each treatment group, were trypsinised
into single cells and then split into two equal fractions. One fraction
had no further additions and the other had the cytolytic anti-Fas
antibody JO2 added at a 1:20 dilution of the antibody as supplied.
All samples were then incubated at 37‡C and cell numbers determined
at timed intervals, by counting on a haemocytometer slide.
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2.4. Use of acridine orange cytochemistry to visualise apoptotic cells
Acridine orange cytochemistry was used for determination of apop-
totic nuclei and has been validated by us, alongside other measure-
ments of apoptosis [2]. Modi¢cations of our published acridine meth-
od were used. Following treatments, islets were trypsinised,
centrifuged at 200Ug and single cells resuspended in approximately
20 Wl medium. A 10 Wl aliquot was mixed with an equal volume of
20 Wg/ml acridine orange, transferred to a microscope slide and
viewed using a broad band £uorescence ¢lter set, excitation range
450^490 nm. Under these conditions, in control cells acridine orange,
a weak £uorescent base, remains sequestered in acidic compartments
in the cytoplasm where its £uorescence is quenched, the cytoplasm is
orange and the nucleus a dull green-black. Cells which are apoptotic
have bright green condensed nuclei usually in rounded fragments;
post-apoptotic cells typically have green, rather than orange cyto-
plasm, with apoptotic nuclei. Nuclei were counted and the percentages
of apoptotic and post-apoptotic cells calculated.
2.5. Statistical analysis
Results are presented as means þ S.E.M. Probability was deter-
mined by multivariate analysis of variance using the statistical pack-
age GLIM (NAG, Oxford, UK), one-way analysis of variance, or
Student’s t-test as indicated in the legends to ¢gures.
3. Results
3.1. Growth factors
Cell death by apoptosis was increased by combined cyto-
kine treatment and decreased when islets were pre-treated
with insulin or IGF-1 (Fig. 1). Neonatal rat islet cell rates
of apoptosis were not signi¢cantly altered by growth factor
exposure alone (Fig. 1).
Fas activation was observed following incubation of cyto-
kine-treated islet cells with a cytolytic anti-Fas antibody (Fig.
2). At early time points ^ 15, 30 even 60 min ^ of incubation
with antibody, cell numbers decreased very signi¢cantly versus
cells incubated with no antibody addition (Fig. 2). Fas expres-
sion on cells was increased by combined cytokine treatment
from 2.3 þ 0.1% (n = 12) to 9.3 þ 0.15 (n = 6) as measured by
£ow cytometry on a Coulter Epics Pro¢le 11 analyser (Coulter
Electronics, Krefeld, Germany), using the same anti-Fas anti-
body at a low dilution (1:250 of the antibody as supplied),
together with a £uorescence-conjugated anti-hamster second
antibody.
When equal numbers of control islets and 48 h cytokine-
treated islets were made into single cells, there was a dramatic
di¡erence in cell loss between the two groups (cells/ml: con-
trol 99U104 ; cytokine 29.3U104). At the start of the experi-
ment (time 0 min) it was clear that cytokine-treated islets, pre-
treated with growth factors, showed improved cell recovery on
trypsinisation (cells/ml: cytokine+insulin 42.5U104 ; cytoki-
ne+IGF-1 37.6U104) (Fig. 3). However, this was only partial
protection, as there was still a signi¢cant reduction in cell
survival versus non-cytokine-treated controls.
The contribution of Fas activation to growth factor modu-
lation of cytokine-induced cell death is shown in Fig. 3.
Although pre-treatment with either growth factor gave only
limited protection following trypsinisation, both growth fac-
tors prevented the Fas-mediated component of killing (Fig. 3).
In the absence of cytokine treatment, no Fas-mediated killing
was observed (data not shown). When a multivariate analysis
of variance was performed on the data, using the statistical
package GLIM, the following conclusions were apparent: (i)
there was no signi¢cant di¡erence in potency between insulin
and IGF-1; (ii) the anti-fas antibody caused a highly signi¢-
cant decrease in survival in cytokine-treated cells (P6 0.001),
although the size of the e¡ect varied between experiments; (iii)
insulin and IGF-1 gave a highly signi¢cant (P6 0.001) in-
crease in survival in cytokine-treated cells; (iv) the protective
e¡ect of insulin and IGF-1 was largely con¢ned to anti-Fas-
treated cells. In the absence of anti-Fas antibody, the protec-
tive e¡ect was signi¢cantly smaller (P6 0.001).
4. Discussion
We have shown that IGF-1 and insulin protect neonatal rat
pancreatic islets from cytokine-mediated cell death and pro-
tect islet cells from Fas-mediated apoptosis. The protection to
single cells that growth factor pre-treatment o¡ers is most
apparent in the ¢rst 2 h following trypsinisation. After this
time, cell loss reaches a plateau and di¡erences in cell loss
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Fig. 1. Combined cytokine treatment of neonatal rat islets (IL-1L,
TNF-K, IFN-Q, 48 h) results in increased apoptosis as determined
by acridine orange cytochemistry. Pre-treatment (24 h) of neonatal
rat islets with growth factors insulin (25 ng/ml) or IGF-1 (1038 M)
signi¢cantly lowered cytokine-induced apoptosis. Results are the
means þ S.E.M. of apoptosis determinations in at least 1500 nuclei
in ¢ve separate experiments. *P6 0.05, **P6 0.01 versus cytokine-
treated without growth factor pre-treatment, by Student’s t-test.
Fig. 2. Neonatal rat islets were treated with IL-1L, TNF-K, IFN-Q
for 48 h. Following trypsinisation, cells were split into two groups,
one was treated with anti-Fas antibody and the other had no addi-
tions. Both groups were incubated at 37‡C, aliquots were removed
for cell counting at timed intervals. Addition of the anti-Fas anti-
body resulted in rapid onset of cell death. Results are the means
þ S.E.M. of 15 replicates within three experiments. ***P6 0.001
versus value at time 0; 22P6 0.01, 222P6 0.001 versus treatment
with anti-Fas antibody, by one-way ANOVA.
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between growth factor-pre-treated and non-pre-treated cells
become non-signi¢cant (data for up to 5 h not shown).
When growth factor-pre-treated, cytokine-treated islets are
trypsinised and incubated with anti-Fas antibody the growth
factors appear to allow cell loss at a level similar to that of the
cytokine-treated islets not incubated with the anti-Fas anti-
body. Growth factor protection o¡ered to the non-antibody-
treated islet cells, post trypsinisation, is barely signi¢cant com-
pared to improvement in cell survival in islet cells exposed to
the anti-Fas antibody. It would appear that the growth factors
indeed protect the single cells from Fas-mediated apoptosis.
There are two main mechanisms by which protection could be
conferred. The ¢rst is through a physical protection, i.e.
growth factor pre-treatment resulting in an accumulation of
extracellular matrix around islet cells which may prevent the
Fas receptor from being bound by the anti-Fas antibody.
Support for this possibility comes from work using another
growth factor, transforming growth factor L (TGF-L). TGF-L
induction of extracellular matrix proteins has been shown to
make murine ¢broblasts resistant to tumour necrosis factor
cytotoxicity [17].
The second mechanism of protection could be occurring
through modulation of signalling pathway(s) involved in
apoptosis. IGF-1 has previously been shown by us to reverse
cytokine-mediated apoptosis and to decrease NOS expression.
Some of its anti-apoptotic e¡ects may be due to lowering
NOS expression as an arginine analogue also confers protec-
tion [6]. Furthermore, if Fas expression is NO-dependent to a
degree, it is possible that IGF-1 may provide partial protec-
tion from Fas-mediated apoptosis via this route.
It is more likely that there are multiple signalling pathways
for both IGF-1 and insulin protection from apoptosis.
Growth factors, including IGF-1 and insulin, have been
shown to trigger the activation of phosphatidylinositol 3P-kin-
ase (PI3K) [18]. PI3K signalling is important to cell survival
and its activation can result in suppression of apoptosis [19],
including in cells which have become detached from their ex-
tracellular matrix [20]. IGF-1 has been purported to inhibit
apoptosis in other cell types via the PI3K and mitogen-acti-
vated protein kinase (MAP kinase) pathways [21]. There may
well be a role for this signalling pathway in suppression of
Fas-mediated apoptosis.
The cytokines IFN-Q, TNF-K and IL-1L are all capable of
inducing Fas expression on neonatal rat islets. The level of
Fas expression is increased when they are used in combination
and increases further with increased IFN-Q dosage [22].
We have shown that Fas-expressing islet cells incubated
with the agonistic anti-Fas antibody experience a signi¢cantly
greater cell loss when compared to those not exposed to the
antibody. This indicates that islets, when primed to express
Fas through cytokine treatment, are capable of undergoing
Fas-mediated apoptosis for example in the presence of the
Fas ligand.
That cytokines are damaging to pancreatic islets has been
known for a number of years and the link with Fas expression
has been shown in other species. It is not known whether
endogenous Fas ligand contributes to islet cell killing or has
contributed prior to trypsinisation. Results of timed cell
counts show that the cross-linking of the Fas receptor results
in rapid onset of apoptosis, but it is not possible to say
whether this is in addition to, or in place of, further late
apoptosis, as cell survival is limited once islets have been
made into single cells. It is also interesting to note that in
islet cells where L-cell surface antigen expression revealed
90% L-cells, these same cells showed modest expression of
Fas (I20%) [22], which raises questions about the timing
and regulating of Fas induction by cytokines.
Although Fas-mediated cell death may play a role initially
following trypsinisation and Fas activation, it is clearly not
the only mechanism by which cytokine-treated cell die. How-
ever, it is the ¢rst time that functional Fas activity has been
shown in neonatal rat L-cells and, more importantly, that the
growth factors insulin and IGF-1 directly a¡ect the Fas-medi-
ated apoptotic pathway.
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Fig. 3. Neonatal rat islets were pre-treated with insulin or IGF-1 for 24 h followed by 48 h treatment with combined cytokines (IL-1L, TNF-K,
IFN-Q). After trypsinisation (time 0), single cells were incubated at 37‡C with or without cytolytic anti-Fas antibody. Growth factors signi¢-
cantly protected islet cells from Fas-mediated cell death. At 60 min, insulin maintained viability of 4.6 þ 0.7U104 extra cells. In the presence of
accelerated killing by Fas antibody insulin was more protective and this number almost doubled (8.9 þ 0.2U104, P6 0.005). Insulin was e¡ec-
tive at 120 min, IGF-1 protected at 60 but not 120 min. 22P6 0.02, 222P9 0.000 versus treatment without growth factor, *P6 0.05,
***P6 0.001 versus number of cytokine-treated cells at the start of the experiment. Multivariate analysis of variance conclusions are in
Section 3.
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